TY - JOUR
T1 - Telomere integrated scoring system of myelodysplastic syndrome
AU - Park, Hee Sue
AU - Im, Kyongok
AU - Shin, Dong Yeop
AU - Yoon, Sung Soo
AU - Kwon, Sunghoon
AU - Kim, Suhng Wook
AU - Lee, Dong Soon
N1 - Funding Information:
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Korean government (MSIT) (NRF‐2017R1A2A1A17069780). This work was supported by the Ministry of Science and ICT(MSIT) of the Republic of Korea and the National Research Foundation of Korea (NRF‐2020R1A3B3079653).
Funding Information:
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Korean government (MSIT) (NRF-2017R1A2A1A17069780). This work was supported by the Ministry of Science and ICT(MSIT) of the Republic of Korea and the National Research Foundation of Korea (NRF-2020R1A3B3079653).
Publisher Copyright:
© 2023 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
PY - 2023/2
Y1 - 2023/2
N2 - Introduction: Recently, multigene target sequencing is widely performed for the purpose of prognostic prediction and application of targeted therapy. Here, we proposed a new scoring system that encompasses gene variations, telomere length, and Revised International Prognostic Scoring System (IPSS-R) together in Asian myelodysplastic syndrome. Methods: We developed a new scoring model of these variables: age ≥ 65 years + IPSS-R score + ASXL1 mutation + TP53 mutation + Telomere length (<5.37). According to this new scoring system, patients were divided into four groups: very good score cutoff (≤3.0), good (3.0–4.5), poor (4.5–7.0), and very poor (>7.0). Results: The median OS was 170.1, 100.4, 46.0, and 12.0 months for very good, good, poor, and very poor, retrospectively (p < 0.001). Meanwhile, according to the conventional IPSS-R scoring system, the median OS was 141.3, 50.2, 93.0, 36.0, and 16.2 months for very low, low, intermediate, high, and very high, retrospectively (p < 0.001). Conclusions: The newly developed model incorporating molecular variations and TL yielded more clear separations of the survival curves. By adding the presence of gene mutation and telomere length to the existing IPSS-R, its predictive ability can be further improved in myelodysplastic syndrome.
AB - Introduction: Recently, multigene target sequencing is widely performed for the purpose of prognostic prediction and application of targeted therapy. Here, we proposed a new scoring system that encompasses gene variations, telomere length, and Revised International Prognostic Scoring System (IPSS-R) together in Asian myelodysplastic syndrome. Methods: We developed a new scoring model of these variables: age ≥ 65 years + IPSS-R score + ASXL1 mutation + TP53 mutation + Telomere length (<5.37). According to this new scoring system, patients were divided into four groups: very good score cutoff (≤3.0), good (3.0–4.5), poor (4.5–7.0), and very poor (>7.0). Results: The median OS was 170.1, 100.4, 46.0, and 12.0 months for very good, good, poor, and very poor, retrospectively (p < 0.001). Meanwhile, according to the conventional IPSS-R scoring system, the median OS was 141.3, 50.2, 93.0, 36.0, and 16.2 months for very low, low, intermediate, high, and very high, retrospectively (p < 0.001). Conclusions: The newly developed model incorporating molecular variations and TL yielded more clear separations of the survival curves. By adding the presence of gene mutation and telomere length to the existing IPSS-R, its predictive ability can be further improved in myelodysplastic syndrome.
KW - Revised International Prognostic Scoring System
KW - myelodysplastic syndrome
KW - targeted capture sequencing
KW - telomere length
UR - http://www.scopus.com/inward/record.url?scp=85147037676&partnerID=8YFLogxK
U2 - 10.1002/jcla.24839
DO - 10.1002/jcla.24839
M3 - Article
C2 - 36658792
AN - SCOPUS:85147037676
SN - 0887-8013
VL - 37
JO - Journal of Clinical Laboratory Analysis
JF - Journal of Clinical Laboratory Analysis
IS - 3
M1 - e24839
ER -